BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT ID: NCT04982393
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2021-12-13
2028-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with PH1
Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Alnylam Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Rochester, Minnesota, United States
Clinical Trial Site
Cincinnati, Ohio, United States
Clinical Trial Site
Pittsburgh, Pennsylvania, United States
Clinical Trial Site
Dallas, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Ghent, , Belgium
Clinical Trial Site
Liège, , Belgium
Clinical Trial Site
Hamilton, Ontario, Canada
Clinical Trial Site
Toronto, Ontario, Canada
Clinical Trial Site
Laurier, Quebec, Canada
Clinical Trial Site
Bordeaux, , France
Clinical Trial Site
Lyon, , France
Clinical Trial Site
Paris, , France
Clinical Trial Site
Berlin, , Germany
Clinical Trial Site
Cologne, , Germany
Clinical Trial Site
Hamburg, , Germany
Clinical Trial Site
Jerusalem, , Israel
Clinical Trial Site
Orbassano, Torino, Italy
Clinical Trial Site
Milan, , Italy
Clinical Trial Site
Verona, , Italy
Clinical Trial Site
Amsterdam, , Netherlands
Clinical Trial Site
Santa Cruz de Tenerife, Canary Islands, Spain
Clinical Trial Site
Barcelona, , Spain
Clinical Trial Site
Las Palmas, , Spain
Clinical Trial Site
Bern, , Switzerland
Clinical Trial Site
London, England, United Kingdom
Clinical Trial Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Alnylam Clinical Trial Information Line
Role: CONTACT
Phone: 1-877-256-9526
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-GO1-007
Identifier Type: -
Identifier Source: org_study_id